- Home
- CPBI vs ADVM Comparison
CPBI vs ADVM Comparison
Compare CPBI & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPBI
- ADVM
- Stock Information
- Founded
- CPBI 2023
- ADVM 2006
- Country
- CPBI United States
- ADVM United States
- Employees
- CPBI N/A
- ADVM N/A
- Industry
- CPBI
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CPBI
- ADVM Health Care
- Exchange
- CPBI Nasdaq
- ADVM Nasdaq
- Market Cap
- CPBI 56.9M
- ADVM 47.4M
- IPO Year
- CPBI N/A
- ADVM 2014
- Fundamental
- Price
- CPBI $15.05
- ADVM $2.25
- Analyst Decision
- CPBI
- ADVM Strong Buy
- Analyst Count
- CPBI 0
- ADVM 5
- Target Price
- CPBI N/A
- ADVM $26.40
- AVG Volume (30 Days)
- CPBI 4.2K
- ADVM 186.4K
- Earning Date
- CPBI 01-01-0001
- ADVM 08-11-2025
- Dividend Yield
- CPBI N/A
- ADVM N/A
- EPS Growth
- CPBI 29.70
- ADVM N/A
- EPS
- CPBI 1.62
- ADVM N/A
- Revenue
- CPBI $18,546,000.00
- ADVM $1,000,000.00
- Revenue This Year
- CPBI N/A
- ADVM N/A
- Revenue Next Year
- CPBI N/A
- ADVM $18.82
- P/E Ratio
- CPBI $9.31
- ADVM N/A
- Revenue Growth
- CPBI 13.73
- ADVM N/A
- 52 Week Low
- CPBI $9.99
- ADVM $1.78
- 52 Week High
- CPBI $15.50
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- CPBI 60.83
- ADVM 40.11
- Support Level
- CPBI $14.85
- ADVM $2.21
- Resistance Level
- CPBI $14.99
- ADVM $3.10
- Average True Range (ATR)
- CPBI 0.09
- ADVM 0.22
- MACD
- CPBI 0.04
- ADVM -0.00
- Stochastic Oscillator
- CPBI 100.00
- ADVM 4.49
About CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists primarily of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in our primary market area, as well as commercial real estate loans.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.